ArticleAnnals of surgery2023
Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer.
Article in Annals of surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 61 citations in OpenAlex.
- Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer.Annals of surgical oncology · 2023Trial
- CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8Annals of gastroenterological surgery · 2026Article
- Treatment-dependent and independent prognostic value of inflammation-based nutritional indices in immune checkpoint inhibitor-based therapy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Review
- Development and validation of a collagen score-based prediction model for neoadjuvant chemoimmunotherapy efficacy in locally advanced esophageal squamous cell carcinoma.Journal of thoracic disease · 2026Article
- Early increase of CD103 expression on peripheral PD-1Cancer immunology, immunotherapy : CII · 2026Observational
- NY-ESO-1 and PD-L1 as biomarkers associated with nivolumab response and outcome in unresectable or recurrent esophageal squamous cell carcinoma: a multicenter biomarker study.Cancer immunology, immunotherapy : CII · 2026Article
- Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients.Cancer science · 2026Article
- AI-driven spatial mapping of myxoid stroma and tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.International journal of surgery (London, England) · 2026Article
- Immunoscore based on CD3American journal of cancer research · 2026Article
- The size of CD8+ infiltrating T cells is a prognostic marker for esophageal squamous cell carcinoma.Scientific reports · 2025Article
- Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable/recurrent esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Review
- ASO Author Reflections: CD45RO-Positive Memory T Cell Density in the Tumoral Core and Invasive Margin as an Immune-Related Prognostic Marker in Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2025Article
- CD45RO-Positive Memory T-Cell Density in the Tumoral Core and Invasive Margin Predict Long-Term Survival in Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2025Article
- Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma.Translational lung cancer research · 2024Article
- Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.Cancer science · 2024Article
- Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort.Esophagus : official journal of the Japan Esophageal Society · 2024Article
- In situ analysis of CCR8BMC cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTumor-infiltrating lymphocytes (TILs) have long been recognized as playing an important role in tumor immune microenvironment. Lately, the Immunoscore (IS) has been proposed as a new method of quantifying the number of TILs in association with patient survival in several cancer types.
methodsIn 300 preoperatively untreated esophageal cancer (EC) patients who underwent curative resection at two different institutes, immunohistochemical staining using CD3 and CD8 antibodies was performed to evaluate IS, as objectively scored by auto-counted TILs in the tumor core and invasive margin. In addition, in pre-neoadjuvant chemotherapy (pre-NAC) endoscopic biopsies of a different cohort of 146 EC patients who received NAC, CD3, and CD8 were immunostained to evaluate TIL density.
resultsIn all cases, the IS-high (score 3-4) group tended to have better survival [5-year overall survival (OS) of the IS-high vs low group: 77.6 vs 65.8%, P = 0.0722] than the IS-low (score 1-2) group. This trend was more remarkable in cStage II-IV patients (70.2 vs 54.5%, P = 0.0208) and multivariate analysis of OS further identified IS (hazard ratio 2.07, P = 0.0043) to be an independent prognostic variable. In preNAC biopsies, NAC-responders had higher densities than non-responders of both CD3 + ( P = 0.0106) and CD8 + cells ( P = 0.0729) and, particularly CD3 + cell density was found to be an independent prognostic factor (hazard ratio 1.75, P = 0.0169).
conclusionsThe IS signature in surgical specimens and TIL density in preNAC- biopsies could be predictive markers of clinical outcomes in EC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.